Dr. Rameen Moridzadeh, MD

Dr. Moridzadeh practices at Linden Surgical Center of Beverly Hills in Beverly Hills, California.

Dr. Moridzadeh's NPI, 1427445675, was assigned on April 24, 2015. Dr. Moridzadeh graduated from New York University School of Medicine in 2015. Dr. Moridzadeh holds California license A146962.

Dr. Moridzadeh's primary practice is Linden Surgical Center of Beverly Hills, at 9735 Wilshire Boulevard, Suite 100, Beverly Hills, CA 90212. The practice phone is (310) 858-6582.

Dr. Moridzadeh's primary practice is Linden Surgical Center of Beverly Hills in Beverly Hills, California. Dr. Moridzadeh is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Moridzadeh to 2 more hospitals, 5 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Moridzadeh practices, 5 sites in all. Vendor and product names are available with a free account.

Vascular surgery is Dr. Moridzadeh's primary specialty in the NPI Registry, under taxonomy code 2086S0129X. Dr. Moridzadeh is board certified in vascular surgery by the American Board of Surgery. Dr. Moridzadeh is licensed in California.

Dmand AI lists arterial blot clot /embolism, blood vessel access for dialysis, carotid revascularization, chronic skin ulcer, circulatory problems in extremities, deep vein thrombosis (DVT), heart device and aorta surgery and leg revascularization among the conditions Dr. Moridzadeh treats.

CMS data shows 4,967 Medicare services from Dr. Moridzadeh across 36 procedure codes in 2024, for 1,805 Medicare patients. Medicare paid $2,014,451 for them.

CMS counts 1,805 Medicare patients who saw Dr. Moridzadeh in 2024. The largest group is 75 to 84, with 683 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 40% are also on Medicaid. Their average risk score is 2.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Moridzadeh's median patient age at 66, with 51% women.

In 2024, Dr. Moridzadeh wrote 98 Medicare Part D claims for 36 patients. 51% of them were for generic drugs. CMS names the drug for 73 of them, across 2 drugs with 11 or more claims each, at $24,755 in total drug cost. In 2023, CMS named 85 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Moridzadeh for performance year 2024, reported as part of a group. Dr. Moridzadeh accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Moridzadeh as offering telehealth. CMS counts 83 procedures of leg revascularization (restoring blood flow) by Dr. Moridzadeh, more than 98% of the clinicians it reports for that procedure.

Dmand AI links 3 papers to Dr. Moridzadeh, published from 2011 to 2013. Dr. Moridzadeh's most frequent co-authors are Mark Adelman, MD, Kim A. Eagle, MD and Karan Garg, MD.

CMS Open Payments shows 210 general payments to Dr. Moridzadeh from 42 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 49% of the total. Medtronic, Inc. paid the most, $6,067.

Dr. Moridzadeh graduated from New York University School of Medicine in 2015.

Dr. Moridzadeh is in network with 15 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.